Rezatapopt clinical trials
Also written PC14586.
How each study uses rezatapopt is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rezatapopt studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
PMV Pharmaceuticals, Inc (5) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test rezatapopt.
- Dec 2026The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Phase 1/2 · PMV Pharmaceuticals, Inc
- Mar 2027A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.Phase 1 · PMV Pharmaceuticals, Inc
- Aug 2027A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)Phase 1 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses rezatapopt is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)RecruitingPhase 1M.D. Anderson Cancer CenterNCT06616636Written as Rezatapopt
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)RecruitingPhase 1/2PMV Pharmaceuticals, IncNCT04585750Written as rezatapopt
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.RecruitingPhase 1PMV Pharmaceuticals, IncNCT07372625Written as rezatapopt
- Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese VolunteersCompletedPhase 1PMV Pharmaceuticals, IncNCT05249348Written as PC14586
- A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy ParticipantsCompletedPhase 1PMV Pharmaceuticals, IncNCT06362642Written as PC14586
- AME Study of [14C]-PC14586 in Healthy Male ParticipantsCompletedPhase 1PMV Pharmaceuticals, IncNCT05523687Written as [14C]-PC14586
Given beside what is tested · 1 — rezatapopt is usual care or a partner of the new treatment
Codes
What other systems call rezatapopt · ClinicalTrials.gg INT015134
- UNII (FDA) 5W59S33KC9REZATAPOPTOne source FDA
- NCI Thesaurus C203051RezatapoptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5W59S33KC9 | REZATAPOPT | One source FDA |
| NCI Thesaurus | C203051 | Rezatapopt | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.